Jazz Pharmaceuticals PLC (NAS:JAZZ)
$ 109.74 -2.27 (-2.03%) Market Cap: 6.92 Bil Enterprise Value: 11.03 Bil PE Ratio: 22.63 PB Ratio: 1.87 GF Score: 78/100

Jazz Pharmaceuticals PLC at Bank of America Merrill Lynch Global Healthcare Conference (Virtual) Transcript

Sep 18, 2020 / 03:45PM GMT
Release Date Price: $141.9 (+1.25%)
Jason Matthew Gerberry
BofA Merrill Lynch, Research Division - MD in US Equity Research

Good day, everybody. My name is Jason Gerberry. I cover Smid cap biotech and specialty pharma at Bank of America. I am pleased to be introducing our next company presenter at the BofA Global Healthcare Conference. I'm pleased to be introducing Jazz Pharmaceuticals and COO, Dan Swisher.

Jazz is known for its lead position in sleep medicines but also has an ever-growing oncology portfolio. So interested to talk about the company's expanding pipeline and on market business.

So Dan, thanks so much for joining us today.

Daniel N. Swisher
Jazz Pharmaceuticals plc - President & COO

Yes. Thanks, Jason, for having us.

Questions & Answers

Jason Matthew Gerberry
BofA Merrill Lynch, Research Division - MD in US Equity Research

So maybe we can just jump into Q&A here. And obviously, the company has a substantial blockbuster drug in Xyrem and coming along with that is positives and some negatives. A

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot